Lek d.d.
Lek d.d. is a Slovenian pharmaceutical company founded in 1946 that develops, produces, and distributes generic pharmaceuticals for healthcare providers internationally, with operations spanning Slovenia, Kazakhstan, and the Philippines, supported by government-backed bilateral trade channels and high-tech manufacturing initiatives.
- Company typePrivate
- Founded1946
- HeadquartersLjubljana, Slovenia
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lek d.d. does
Lek d.d. is a Slovenian pharmaceutical company founded in 1946, headquartered in Ljubljana, that develops, produces, and distributes generic pharmaceuticals for customers worldwide. The company employs 251-500 people and serves healthcare providers and pharmacies as its primary customer segment, with a secondary focus on government agencies for strategic partnerships and bilateral trade initiatives.
The company's operations extend beyond core pharmaceutical manufacturing into diversified high-tech sectors, including semiconductor manufacturing operations in Batangas, Philippines, and business internet services. Lek benefits from significant Slovenian government support, having received a 42 million EUR grant in 2025 for high-tech project development, which positions it as a strategically important national enterprise. The company maintains active international market presence in Central Asia (Kazakhstan) and Southeast Asia (Philippines), accessing these markets through bilateral trade channels and government-facilitated partnerships rather than conventional commercial sales channels.
Lek's business model is anchored in pharmaceutical product distribution and manufacturing, with revenue generated through recurring product sales and hardware-related manufacturing operations. The company is privately held with no publicly identified parent company. Its go-to-market relies heavily on government-backed bilateral trade relationships and participation in international business forums, suggesting a distribution model that leverages state-level diplomatic and economic relationships rather than direct consumer marketing. Recent evidence indicates a strategic pivot toward high-tech capabilities funded by government grants, potentially transforming the company from a pure-play generics manufacturer into a diversified pharmaceutical-technology enterprise.
Lek d.d. firmographics
Firmographics- Name
- Lek d.d.
- Legal name
- Lek d.d.
- Website
- https://tabijastrology.in
- Company type
- Private
- Founded year
- 1946
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Lek d.d. is a Slovenian pharmaceutical company founded in 1946 that develops, produces, and distributes generic pharmaceuticals for healthcare providers internationally, with operations spanning Slovenia, Kazakhstan, and the Philippines, supported by government-backed bilateral trade channels and high-tech manufacturing initiatives.
- Ownership category
- akta.pro rank
Lek d.d. industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)
Keywords
Where Lek d.d. is headquartered
LocationHeadquarters
- HQ city
- Ljubljana
- HQ country
- Slovenia
- HQ region
- Europe
Markets served
Lek d.d. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical products: Lek d.d. operates as a pharmaceutical company producing and distributing pharmaceutical products internationally across markets including Southeast Asia and Central Asia
- Manufacturing operations: Operations in semiconductor manufacturing in Batangas, Philippines and business internet services indicating diversified manufacturing capabilities
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Lek d.d. product offering
Product offeringCore offering
Lek d.d. develops, produces, and distributes generic pharmaceutical products for international markets, with manufacturing operations based in Slovenia and adjacent semiconductor manufacturing activities in the Philippines. The company maintains active market operations in Kazakhstan and participates in bilateral pharmaceutical trade across Southeast Asia and Central Asia.
Product overview
Lek d.d. is a Slovenian pharmaceutical and healthcare company with a high-tech project portfolio. The company operates in semiconductor manufacturing in the Philippines and maintains business activities in Kazakhstan's market. The company has received Slovenian government support through a grant of up to 42 million euros for its high-tech initiatives. No specific branded products, modules, or named offerings are documented in the available sources.
Differentiator
Problem solved
Functional benefit
Companies that use Lek d.d.
Customer profileSegments2 records
Ideal customer profiles2 records
Lek d.d. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lek d.d. partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Philippine Government AgenciesminorMultiple Philippine government agencies are participating in a two-day matchmaking session with Slovenian companies including Lek, focusing on science-to-business collaboration, decarbonization, and AI in disaster management.
- Republic of KazakhstanminorLek is already active in the Kazakh market alongside other Slovenian companies including Iskra, Gorenje, and Krka. Presidents of both countries discussed expanded economic cooperation at the Kazakhstan-Slovenia Business Forum.
Scale indicators3 records
Recent moves5 records
Expansion highlights5 records
Lek d.d. competitors and assessment
Company assessmentDirect peers
- Polpharma: Polpharma is one of the largest Polish generic pharmaceutical manufacturers with active presence in Central Asian markets. Comparable in product category, generics manufacturing model, and regional expansion strategy.
- Gedeon Richter: Gedeon Richter is a Hungarian-headquartered generic and specialty pharmaceutical manufacturer with deep Central/Eastern European presence. Comparable in scale, product focus (generics + biosimilars), and regional market strategy.
- Stada Arzneimittel: Stada is a European-focused generic and specialty pharmaceutical manufacturer headquartered in Germany with strong Central/Eastern European presence. Comparable product mix (generics + biosimilars) and similar regional market focus to Lek d.d.
- Krka: Krka is a Slovenian-headquartered generic pharmaceutical manufacturer with similar product profile, geographic reach across Central/Eastern Europe, and an international expansion model. It is co-mentioned with Lek d.d. in the Kazakhstan–Slovenia Business Forum, making it the closest direct peer.
- Zentiva: Zentiva is a European generics manufacturer headquartered in Prague with strong presence in Central/Eastern Europe. Comparable product portfolio and regional market focus to Lek d.d.
Broad incumbents
- Sandoz: Sandoz is a global leader in generics and biosimilars with multi-billion-dollar scale; historically Lek d.d. was a Sandoz subsidiary. Comparable in product category (generics + biologics manufacturing) but vastly larger and broader in geographic reach.
- Viatris: Viatris is a global pharmaceutical company formed from the Mylan–Upjohn combination with a large generics and biosimilars portfolio. Comparable in product category and target customers (pharmacy supply, public health) but at significantly larger scale.
- Aurobindo Pharma: Aurobindo is one of the largest Indian generic pharmaceutical manufacturers with significant global supply presence. Comparable in generics manufacturing business model but operates at vastly larger scale and lower cost base.
- Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with extensive specialty and biosimilar offerings. Comparable in core generics manufacturing business model but operates at far greater global scale.
Emerging players
- Alvotech: Alvotech is an Iceland-based biosimilars-focused manufacturer with biologics technical capabilities. Comparable in biologics/specialty manufacturing focus but focused exclusively on biosimilars rather than broad generics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Lek d.d. social profiles
Digital presenceLek d.d. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lek d.d. leadership team
Management profileNumber of profiles
Profiles1 record
Lek d.d. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lek d.d. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lek d.d.
What does Lek d.d. do?
Lek d.d. develops, produces, and distributes generic pharmaceutical products for international markets, with manufacturing operations based in Slovenia and adjacent semiconductor manufacturing activities in the Philippines. The company maintains active market operations in Kazakhstan and participates in bilateral pharmaceutical trade across Southeast Asia and Central Asia.
Is Lek d.d. a public or private company?
Lek d.d. is a private company. It is classified as unknown and is currently operating.
When was Lek d.d. founded?
Lek d.d. was founded in 1946. It employs 251 to 500 people.
Where is Lek d.d. based?
Lek d.d. is headquartered in Ljubljana, Slovenia, in the Europe region.
How does Lek d.d. make money?
Two revenue lines are on record. Pharmaceutical products are the primary driver. The others are manufacturing operations.
Who are Lek d.d.'s main competitors?
Direct peers on record are Polpharma, Gedeon Richter, Stada Arzneimittel, Krka and Zentiva. Broad incumbents are Sandoz, Viatris, Aurobindo Pharma and Teva Pharmaceutical Industries. Alvotech is listed as an emerging player.
Does Lek d.d. have an API?
No public API is recorded for Lek d.d..
What industry is Lek d.d. in?
Lek d.d.'s product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.